Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,457.00    6.00 (0.41%)
Bid:
1,464.00
Ask:
1,466.00
Spread: 2.00 (0.137%)
Market Cap: £3.08b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Block listing Interim Review

4 Oct 2021 09:55

RNS Number : 9028N
Hikma Pharmaceuticals Plc
04 October 2021
Β 

Hikma Pharmaceuticals PLC

Β 

Β 

Block Listing Six Monthly Return

Β 

Date: 4 October 2021

Β 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

Β 

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 Ordinary Shares of 10 pence

Β 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

Β 

Β 

Block Listing Six Monthly Return

Β 

Date: 4 October 2021

Β 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

LTIP: 57,502 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

LTIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

LTIP: 0 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

LTIP: 57,502 Ordinary Shares of 10 pence

Β 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

Β 

Block Listing Six Monthly Return

Β 

Date: 4 October 2021

Β 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("2009 MIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

2009 MIP: 136,182 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2009 MIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

2009 MIP: 136,182 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2009 MIP: 0 Ordinary Shares of 10 pence

Β 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

Β 

Block Listing Six Monthly Return

Β 

Date: 4 October 2021

Β 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("2018 MIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

2018 MIP: 1,000,000 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2018 MIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

2018 MIP: 226,506 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2018 MIP: 773,494 Ordinary Shares of 10 pence

Β 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

Β 

Block Listing Six Monthly Return

Β 

Date: 4 October 2021

Β 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

EIP: 1,239,967 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

EIP: 350,000 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

EIP: 340,434 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

EIP: 1,249,533 Ordinary Shares of 10 pence

Β 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

Β 

LEI: 549300BNS685UXH4JI75

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
BLRUPGCAUUPGURC
Date   Source Headline
14th Feb 20123:00 pmRNSTotal Voting Rights
2nd Feb 201211:14 amRNSHolding(s) in Company
1st Feb 20121:26 pmRNSDirector Declaration
17th Jan 201210:39 amRNSTender Offer
13th Jan 201210:16 amRNSDirector/PDMR Shareholding
12th Jan 201210:07 amRNSTotal Voting Rights
22nd Dec 201110:39 amRNSAdditional Listing
2nd Dec 201111:28 amRNSTender Offer
1st Dec 20114:14 pmRNSHolding(s) in Company
11th Nov 201111:25 amRNSTotal Voting Rights
4th Nov 20117:00 amRNSInterim Management Statement
24th Oct 20115:34 pmRNSDirector/PDMR Shareholding
18th Oct 201112:59 pmRNSDirector/PDMR Shareholding
18th Oct 201112:58 pmRNSDirector/PDMR Shareholding
18th Oct 201112:39 pmRNSDirector/PDMR Shareholding
17th Oct 20119:00 amRNSTender Offer
7th Oct 20111:14 pmRNSBlocklisting Interim Review
6th Oct 20113:26 pmRNSDividend Declaration
3rd Oct 20114:33 pmRNSAcquisition
25th Aug 20117:00 amRNSDirectorate Change
25th Aug 20117:00 amRNSInterim Results
19th Aug 20112:21 pmRNSTrading Statement
26th Jul 201110:54 amRNSTotal Voting Rights
11th Jul 20117:00 amRNSHikma enhances its API sourcing capabilities
1st Jun 20114:01 pmRNSTotal Voting Rights
26th May 201112:03 pmRNSDirector/PDMR Shareholding
25th May 20114:01 pmRNSHolding(s) in Company
17th May 20114:12 pmRNSDirector/PDMR Shareholding
13th May 20112:10 pmRNSDirector/PDMR Shareholding
13th May 20112:04 pmRNSDividend Declaration
12th May 201112:19 pmRNSAGM Statement
12th May 20117:00 amRNSInterim Management Statement
9th May 20115:45 pmRNSDirector/PDMR Shareholding
9th May 201112:04 pmRNSTotal Voting Rights
9th May 201112:01 pmRNSAnnual Information Update
3rd May 20117:00 amRNSStatement re Completion of Acquisition
15th Apr 20117:00 amRNSRe Agreement with Unimark Remedies Limited
14th Apr 20114:04 pmRNSAnnual Information Update
13th Apr 201112:07 pmRNSDirector/PDMR Shareholding
4th Apr 20112:33 pmRNSDirector/PDMR Shareholding
18th Mar 20114:05 pmRNSDirector/PDMR Shareholding
16th Mar 20117:00 amRNSPreliminary Results
2nd Mar 20119:55 amRNSTotal Voting Rights
8th Feb 201112:56 pmRNSTotal Voting Rights
3rd Feb 201110:21 amRNSHolding(s) in Company
24th Jan 20119:00 amRNSAppointments
12th Jan 20115:14 pmRNSTotal Voting Rights
12th Jan 201110:13 amRNSDirector/PDMR Shareholding
10th Jan 20113:47 pmRNSDirector/PDMR Shareholding
10th Jan 201111:51 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.